An Australian firm filed a THC-free CBD pain tablet with TGA approval in mind, but its own trial reportedly didn’t beat placebo—raising product, market, and investor questions.

A University of Michigan–led analysis reported in Annals of Internal Medicine finds a 16% rise since 2020 in U.S. clinicians authorizing medical cannabis, with millions of patients participating.

Steven Froelich’s cocaine tale from Guatemala hits High Times. Here’s what it is (a personal narrative), what it isn’t (a policy change), and why DMV readers should care.

Marijuana Venture reports a hands-on hempcrete workshop outside Santa Cruz on August 22–23. Here’s why the training matters and what DMV readers should watch next.

Psychedelic Alpha has introduced The Psychedelic News Feed Podcast, creating a new way to follow psychedelics developments. Here’s why DMV readers should care.

A new Cannabis Wire conversation with Alice O’Leary Randall invites a fresh look at patient access and the fast-changing world of marijuana delivery regulations and compliance.

Clinical trial momentum has regulators eyeing MDMA and psilocybin. Here’s how “abuse potential” factors into rescheduling talks—and what DMV readers should watch.

Psychedelic Alpha reports that two psychiatrists in New Zealand have been cleared to prescribe MDMA for PTSD. Here’s what happened and what DMV readers should know.